ERBB2 and breast carcinoma: In addition, sacituzumab govitecan-hziy has been approved by the FDA for the treatment of HR + /HER2 − advanced breast cancer patients who have previously undergone endocrine-based treatments and at least two other therapeutic regimens [104].